News & Updates
Filter by Specialty:

Real-world data support DOACs over warfarin for VTE
The direct oral anticoagulants (DOACs) apixaban and rivaroxaban trump warfarin for the treatment of venous thromboembolism (VTE) in a retrospective observational analysis comprising real-world VTE patients from Finland, Norway, and Sweden.
Real-world data support DOACs over warfarin for VTE
12 Jul 2024
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
12 Jul 2024
Novel antireflux device shows potential for treatment of PPI-refractory GERD
Patients suffering from gastroesophageal reflux disease (GERD) and ineffective esophageal motility (IEM) may benefit from the novel RefluxStop device implantation, a safe and minimally invasive technology that offers potential benefits, a study has shown.
Novel antireflux device shows potential for treatment of PPI-refractory GERD
11 Jul 2024
Statin use tied to joint replacement risk
A French study presented at EULAR 2024 reveals an association between statin treatment and an increased risk of total joint replacement in individuals with knee and hip osteoarthritis (OA).